Blood sugar monitoring in people with type 2 diabetes and cancer

Not Applicable

• Conditions: Type 2 diabetes and cancer; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN14005743
• Lead Sponsor: niversity of Leeds

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-17
• Last Update Posted: 29 July 2024
• Study Completion: 2026-09-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 202

Inclusion Criteria

1. Aged >=18 years at the time of cancer diagnosis
2. Biopsy-confirmed cancer of the colon, rectum, breast or lung. High-grade dysplasia is acceptable with unequivocal radiological evidence of invasive cancer
3. Prior diagnosis of type 2 diabetes (T2D) recorded in primary or secondary care (diet-controlled or requiring hypoglycaemic therapies [including insulin])
4. Cancer care being undertaken at, or managed by, the Leeds Teaching Hospitals NHS Trust, Calderdale and Huddersfield NHS Foundation Trust, Hull University Teaching Hospitals NHS Trust or Sheffield Teaching Hospitals NHS Foundation Trust
5. Planned treatment for cancer includes chemotherapy

Exclusion Criteria

1. Diabetes mellitus diagnosed during the course of active cancer treatment
2. Any diabetes other than T2D
3. Already using the FreeStyle Libre device
4. Inability to give informed consent
5. Known sensitivity to medical adhesives likely to result in an adverse reaction to the Libre device
6. Deemed not suitable for inclusion by study investigators
7. Previous treatment with chemotherapy within 6 months
8. Have a pacemaker or any other neurostimulator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Completion of planned chemotherapy treatment is calculated from instances of dose reduction, early termination of planned treatment and pause in planned treatment at days 14, 21, 28, 90 and 180